MEMORIAL DAY OFFER 50% OFF Premium Subscription Order Now MEMORIAL DAY 50% OFF Subscription >>

No Pain, No Gain.Week 21 On Stock Market Click to watch.

Capricor Therapeutics Stock Forecast

NASDAQ:CAPR BUY SELL

$3.64 (4.90%)

Volume: 125.223k

Closed: May 27, 2022

Hollow Logo Score: 4.193

Capricor Therapeutics Stock Forecast

BUY SELL NASDAQ:CAPR
$3.64 (4.90%)

Volume: 125.223k

Closed: May 27, 2022

Score Hollow Logo 4.193

Capricor Therapeutics Company Profile

8840 Wilshire Boulevard

Beverly Hills CA 90211

310-358-3200

www.capricor.com

Industry: Biotechnology

Sector: Healthcare

Capricor Therapeutics

Description

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company’s development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials, as well as CAP-1001, which has completed Phase I clinical trial; and CU-NP and CSps. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE